(156 days)
The HAIC assay used on the Dimension® clinical chemistry system is an in vitro diagnostic assay for the quantitative determination of percent hemoglobin Alc (HbAIc) in anticoagulated whole blood. Measurements of percent hemoglobin A1c are effective in monitoring long term glucose control in individuals with diabetes mellitus.
The Dimension® HA1C assay measures both HbA1c and hemoglobin. The HbA1c measurement is based on a turbidimetric inhibition immunoassay (TINIA) principle, and the measurement of total hemoglobin is based on a modification of the alkaline hematin reaction. Using the values obtained for each of these two analytes (in g/dL), the percentage of the total hemoglobin that is glycated is calculated and reported as %HbA1c. The final %HbAlc result has been standardized to the results obtained in the Diabetes Control and Complications Trial (DCCT). Pre-treatment to remove the labile fraction is not necessary as only the Amadori rearranged form of HbA1c is detected. All hemoglobin variants that are glycated at the beta-chain N-terminus and have epitopes identical to that of HbA lc, are measured by this assay.
The provided text does not contain information about an AI device or a study involving human readers or expert adjudication for a test set. This document describes the "Dimension® HA1C Assay," which is an in vitro diagnostic assay for measuring hemoglobin A1c. It's a chemical assay, not an AI-powered device. Therefore, many of the requested fields cannot be filled.
However, I can extract information related to the device's performance given the available text.
1. A table of acceptance criteria and the reported device performance
The primary "acceptance criteria" here is substantial equivalence to the predicate device. The performance is reported as a correlation between the two methods.
| Acceptance Criteria / Performance Metric | Reported Device Performance (Dimension® HA1C Assay) |
|---|---|
| Correlation Coefficient with Predicate Device (Roche Tina-quant® HBA1C II) | 0.994 |
| Slope of correlation with Predicate Device | 0.985 |
| Intercept of correlation with Predicate Device | 0.3% HbA1c |
2. Sample sized used for the test set and the data provenance
- Sample Size: 136 anticoagulated whole blood samples
- Data Provenance: The document doesn't explicitly state the country of origin. It indicates these were "anticoagulated whole blood samples" used for "method correlation" with a legally marketed predicate device, implying they were likely collected in a clinical setting in the region where the study was conducted (presumably the US, given the FDA submission). It is a retrospective comparison or split-sample study as existing samples were tested on both devices.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable, as this is a chemical assay comparison, not an imaging or diagnostic device requiring expert interpretation of ground truth. The "ground truth" for this device's performance is its correlation with a recognized predicate device.
4. Adjudication method for the test set
Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. No AI component or human reader study is described.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Yes, in a sense, the device's performance was evaluated in a standalone manner by comparing its results to a predicate device. It's an automated chemical analysis, so human intervention in the result generation itself is minimal once the sample is prepared.
7. The type of ground truth used
The "ground truth" for proving substantial equivalence was the results obtained from a legally marketed and established predicate device, the Roche Tina-quant® HBA1C II assay. This is a form of comparative reference standard.
8. The sample size for the training set
Not applicable. This device is a chemical assay, not a machine learning model, so there is no "training set."
9. How the ground truth for the training set was established
Not applicable.
{0}------------------------------------------------
NOV 1 5 2001
DADE BEHRING INC. 0. Box 6101 Newark, DE 19714
DADE BEHRING
Summary of Safety and Effectiveness Information
This summary of 510 (k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 607.92
Submitter's Name:
Cathy P. Craft Dade Behring Inc. Building 500. Mailbox 514 P.O. Box 6101 Newark, De 19714-6101 Phone: (302) 631-6280 Fax: (302) 631-6299
June 8, 2001 Date of Preparation:
Device Name: Dimension® HA1C Assay
Classification Name: Glycosylated Hemoglobin
Predicate Device: Roche Tina-quant® HBA1C II
The Dimension® HA1C assay measures both HbA1c and Device Description: hemoglobin. The HbA1c measurement is based on a turbidimetric inhibition immunoassay (TINIA) principle, and the measurement of total hemoglobin is based on a modification of the alkaline hematin reaction. Using the values obtained for each of these two analytes (in g/dL), the percentage of the total hemoglobin that is glycated is calculated and reported as %HbA1c. The final %HbAlc result has been standardized to the results obtained in the Diabetes Control and Complications Trial (DCCT).
Pre-treatment to remove the labile fraction is not necessary as only the Amadori rearranged form of HbA1c is detected. All hemoglobin variants that are glycated at the beta-chain N-terminus and have epitopes identical to that of HbA lc, are measured by this assay.
{1}------------------------------------------------
Principles of Procedure:
Total Hemoglobin Measurement: A sample of whole blood is added to the first cuvette containing lysing reagent. This reagent lyses the red blood cells and simultaneously converts the released hemoglobin to a derivative that has a characteristic absorbance spectrum. An aliquot of the lysed whole blood is transferred from the first cuvette to a second cuvette where total hemoglobin concentration is measured at 405 nm and 700 nm.
Whole blood + lysing agent --> Released hemoglobin → hemoglobin derivative (measured at 405 nm)
Hemoglobin A1c Measurement: The same aliquot of the lysed whole blood which is transferred from the first cuvette to the second cuvette for the Hb measurement is also used for the measurement of HbA1c. The second cuvette contains an anti-HbA1c antibody in a buffered reagent. Hemoglobin A1c in the sample reacts with anti-HbA1c antibody to form a soluble antigen-antibody complex. A polyhapten reagent containing multiple HbAlc epitopes is then added to this cuvette. The polyhapten reacts with excess (free) anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex. The rate of this reaction is measured turbidimetrically at 340 nm and blanked at 700 nm and is inversely proportional to the concentration of HbA1c in the sample.
hemoglobin A1c + anti-HbA1c antibody → hemoglobin A1c -anti-HbA1c antibody complex
anti-HbA1c antibody (excess) + polyhapten → Ab / polyhapten complex (absorbs at 340 nm)
Intended Use:
The HA1C assay on the Dimension® clinical chemistry system is an in vitro diagnostic assay for the quantitative determination of percent hemoglobin Alc (HbA1c) in anticoagulated whole blood. Measurements of percent hemoglobin A 1 c are effective in monitoring long term glucose control in individuals with diabetes mellitus.
| Item | ||
|---|---|---|
| Operating Principle | turbidimetric inhibitionimmunoassay (TINIA) | turbidimetric inhibitionimmunoassay (TINIA) |
| Detection | Hb - Colorimetric at 405nm and 700nmHbA1c - turbidimetric at340 nm blanked at 700 nm | Hb - Colorimetric at 660 nmand 570HbA1c - turbidimetric at 340nm blanked at 700 nm |
| Specimen Type | anticoagulated whole blood | anticoagulated whole blood |
| Sample Pre-treatment | none required | required |
Comparison to Predicate Device:
- Tina-quant is a registered trademark of Roche Diagnostics Corporation
{2}------------------------------------------------
Comments on Substantial Equivalence:
Method correlation between the Roche Tina-quant® HBA1C II on Hitachi and Dimension® HA1C methods was evaluated with 136 anticoagulated whole blood samples ranging from 4.9% to 16.7% HbA1c. These samples provided a correlation coefficient of 0.994, a slope of 0.985, and an intercept of 0.3% HbAlc.
Conclusion:
The HA1C assay on the Dimension® clinical chemistry system is substantially equivalent in principle and performance to the Roche Tina-quant® HBA1C II based on the split sample comparison summarized in the previous section, Comments on Substantial Equivalence.
Cathy P. Craft
Cathy P. Craft Director, Regulatory Affairs Date: June 8, 2001
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features an abstract eagle design with three lines forming the body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV 1 5 2001
Ms. Cathy P. Craft Director, Regulatory Affairs Dade Behring Inc. P.O. Box 6101 Newark, DE 19714
K011852 Re:
Trade/Device Name: Dimension® HAIC Assay Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Code: LCP Dated: August 30, 2001 Received: August 31, 2001
Dear Ms. Craft:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{4}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrb/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
NOV 1 5 2001
Indications For Use Statement
Device Name: Dimension® HA1C Assay
Indications for Use:
The HAIC assay used on the Dimension® clinical chemistry system is an in vitro diagnostic assay for the quantitative determination of percent hemoglobin Alc (HbAIc) in anticoagulated whole blood. Measurements of percent hemoglobin A1c are effective in monitoring long term glucose control in individuals with diabetes mellitus.
Cathy P. Craft Director, Regulatory Affairs June 8, 2001
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| (Division Sign-Off) | |
|---|---|
| --------------------- | -- |
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Division of Clinical Laboratory Devjees | |
|---|---|
| 510(k) Number | K011852/51 |
Prescription Use (Per 21 CRF 801.109) OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)
§ 864.7470 Glycosylated hemoglobin assay.
(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).